CollPlant Biotechnologies Ltd. said its ordinary shares will begin trading on Nasdaq as “OPHI” at the open on November 13, 2026, after closing under “CLGN” on November 12, 2026; no shareholder action is required.
OPHI · CollPlant Biotechnologies Ltd · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
CollPlant Biotechnologies Ltd. subsidiary LightSolver will publicly demonstrate its all-optical Laser Processing Unit at SC26 in Chicago November 16-19, 2026, solving linear equations, differential equations and complex optimization problems, alongside Boeing corrosion-simulation benchmarks.
CollPlant Biotechnologies Ltd. said the Israel Innovation Authority approved an approximately $1.8 million grant for subsidiary LightSolver Ltd. to advance its Laser Processing Unit (LPU) development; receipt remains subject to the authority’s customary terms.
CollPlant Biotechnologies Ltd. proposed changing its name to OptiPhi Computing Ltd. and Nasdaq ticker from “CLGN” to “OPHI,” reflecting expansion into photonic computing after acquiring LightSolver Ltd. in September 2026; shareholder approval is required.
CollPlant Biotechnologies Ltd. appointed Eran Rotem CEO effective November 2, 2026, replacing Yehiel Tal, as part of a cost-reduction plan. The company is discontinuing regenerative medicine research and development but plans to continue rhCollagen production and supply.
CollPlant Biotechnologies Ltd. subsidiary LightSolver signed an agreement with the Directorate of Defense Research & Development within the Israel Ministry of Defense to develop and deliver an LPU, establishing a multi-year framework with an initial order covering the first 12 months.
CollPlant Biotechnologies Ltd. closed a private placement on October 14, 2026, raising approximately $3.7 million gross through 989,301 ordinary shares or pre-funded warrants and warrants for up to 1,483,950 ordinary shares at $3.74 per share.
CollPlant Biotechnologies Ltd. entered agreements for a private placement of 989,301 ordinary shares and warrants for up to 1,483,952 ordinary shares at $3.74 per share, expected to raise approximately $3.7 million and close on or about October 14, 2026.
CollPlant completed its LightSolver acquisition on September 3, 2026. For the six months ended June 30, 2026, revenue was $181,000, net loss was $5.8 million, cash was $2.6 million, and management reported substantial doubt about continuing as a going concern.
On September 24, 2026, CollPlant Biotechnologies Ltd. announced peer-reviewed LightSolver and High-Performance Computing Center Stuttgart research projecting LightSolver LPU time-to-solution acceleration of approximately 40× to more than 80,000× versus GPU algorithms on sparse linear systems.
CollPlant Biotechnologies Ltd. regained Nasdaq compliance with Listing Rule 5550(a)(2), requiring a $1.00 per share minimum bid price; Nasdaq closed the matter after the price met the threshold from September 4, 2026 to September 18, 2026.